Self-guided

<5 minutes

FeNO Is A Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma

Topic: Burden Of Disease Pathophysiology Guidelines & recommendations

Tags: Disease burden  Pathophysiology  Type 2 inflammation  Biomarkers  FeNO  Pediatric asthma 

FeNO Is A Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma.

 

 

 

MAT-US-2200770   V1 03/15/2024

MAT-US-2201151 V1 2/23/2024

Welcome to the ADVENT program website

ADVENT is a medical education program by Sanofi Genzyme and Regeneron. This website is intended only for health care professionals in the US only.

I AM A HEALTHCARE PROVIDER
I AM NOT A HEALTHCARE PROVIDER

ADVENT is a global medical education program by Sanofi Genzyme and Regeneron and is only intended for healthcare providers.

You are leaving the ADVENT program website

Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme websites, and this hyperlink does not constitute an endorsement by Sanofi Genzyme of the site’s content. Sanofi Genzyme’s privacy procedures do not apply to the owners of a non–Sanofi Genzyme website.

LEAVE THIS SITE GO BACK TO ADVENT PROGRAM